Becton is your #1 Spinoff Buy in 2022

Article Excerpt

We have selected Becton Dickinson as your #1 Spinoff Buy for 2022. The medical device maker now plans to set up its diabetes-products business as a separate, publicly listed company. The split should unlock some of Becton’s holding company discount and let it focus on its new products such as COVID-19 testing kits. Moreover, Becton’s spinoff—to be called embecta Corp.–will also be better positioned to launch its own new products and expand in emerging markets. (Currently, those markets contribute just 16% of its revenue). In addition, as a pure-play firm, embecta could become an attractive takeover target. BECTON DICKINSON & CO. $264 is your #1 Spinoff Buy for 2022. The company (New York symbol BDX; Manufacturing sector; Shares outstanding: 285.0 million; Market cap: $75.2 billion; Dividend yield: 1.3%; Takeover Target Rating: Medium; www.bd.com) is one of the world’s largest suppliers of medical products—it makes over 45 billion devices annually. Becton operates through three segments: Medical (47% of fiscal 2021 revenue, 44% of earnings) makes an array of devices for hospitals,…